



INDUSTRY SPONSORED SYMPOSIUM

Thursday, September 9, 2021

05:15–06:15 AM (MT) / 13:15–14:15 PM (CEST)

Redefining the treatment journey in NSCLC with immuno-oncology and EGFR-TKIs



Agenda

Welcome and introduction

Yi-Long Wu

Clinical data with immuno-oncology for unresectable Stage III NSCLC

Suresh Senan

Translating the clinical benefits of EGFR-TKIs across *EGFRm* NSCLC

Zhijie Wang

Panel discussion: Survivorship in NSCLC

Live discussion and audience Q&A, Chaired by Yi-Long Wu



Faculty



Yi-Long Wu (Chair)

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China



Suresh Senan

Amsterdam University Medical Centers, Amsterdam, Netherlands



Zhijie Wang

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China



Meeting objectives

- **To engage with a multidisciplinary international audience about how therapeutic advances with immuno-oncology and EGFR-TKIs are transforming treatment options for patients with NSCLC**
 - To review overall survival with immuno-oncology in unresectable Stage III NSCLC
 - To highlight clinical data with EGFR-TKIs in the treatment of *EGFRm* NSCLC
 - To discuss survivorship in patients with NSCLC in an expert panel